
AI-Powered Personalized mRNA Cancer Vaccines Advance
Moderna and Merck reported that a personalized mRNA therapy, intismeran, combined with Keytruda met key recurrence and distant-metastasis survival endpoints in a prespecified interim analysis. The approach uses AI to select up to 34 tumor-specific neoantigens for an individually manufactured treatment.








